Patents by Inventor Isil Altintas

Isil Altintas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20210277133
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: February 10, 2021
    Publication date: September 9, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20210269541
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: February 10, 2021
    Publication date: September 2, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20210253725
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: January 8, 2021
    Publication date: August 19, 2021
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • Methods of producing multispecific antibodies against CD40 and CD137
    Patent number: 11091557
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: August 17, 2021
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • Multispecific antibodies against CD40 and CD137
    Patent number: 11084882
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Grant
    Filed: April 22, 2020
    Date of Patent: August 10, 2021
    Assignees: GENMAB A/S, BIONTECH SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Friederike Gieseke, Ugur Sahin
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20210163616
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: February 10, 2021
    Publication date: June 3, 2021
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • Binding agents binding to PD-L1 and CD137 and use thereof
    Patent number: 10968280
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: April 6, 2021
    Assignees: GENMAB A/S, BioNTech SE
    Inventors: Isil Altintas, David Satijn, Rik Rademaker, Paul Parren, Ugur Sahin, Friederike Gieseke, Alexander Muik, Christian Grunwitz
  • Agonistic tumor necrosis factor (TNF) receptor binding agents
    Patent number: 10927181
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: February 23, 2021
    Assignees: BIONTECH SE, GENMAB A/S
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137
    Publication number: 20200247899
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Application
    Filed: April 22, 2020
    Publication date: August 6, 2020
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
  • ANTIBODIES AGAINST PD-L1
    Publication number: 20200239579
    Abstract: The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: March 9, 2018
    Publication date: July 30, 2020
    Inventors: Isil ALTINTAS, David SATIJN, Edward VAN DEN BRINK, Dennis VERZIJL, Rik RADEMAKER, Paul PARREN, Bart DE GOEIJ
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20200199229
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: August 19, 2019
    Publication date: June 25, 2020
    Inventors: Edward Norbert VAN DEN BRINK, Joost J. NEIJSSEN, Aran Frank LABRIJN, Joyce MEESTERS, Janine SCHUURMAN, Isil ALTINTAS, Paul PARREN, Rik RADEMAKER
  • BISPECIFIC ANTIBODIES AGAINST CD3 AND CD20
    Publication number: 20200199231
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Application
    Filed: December 4, 2019
    Publication date: June 25, 2020
    Inventors: Patrick ENGELBERTS, Esther BREIJ, Rik RADEMAKER, Isil ALTINTAS, David SATIJN, Sandra VERPLOEGEN, Riemke VAN DIJKHUIZEN RADERSMA, Edward VAN DEN BRINK, Janine SCHUURMAN, Paul PARREN
  • BINDING AGENTS BINDING TO PD-L1 AND CD137 AND USE THEREOF
    Publication number: 20200165349
    Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.
    Type: Application
    Filed: January 31, 2020
    Publication date: May 28, 2020
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Ugur SAHIN, Friederike GIESEKE, Alexander MUIK, Christian GRUNWITZ
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20200079866
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: September 25, 2019
    Publication date: March 12, 2020
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • MULTISPECIFIC ANTIBODIES AGAINST CD40 AND CD137
    Publication number: 20200062853
    Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.
    Type: Application
    Filed: July 14, 2017
    Publication date: February 27, 2020
    Inventors: Isil ALTINTAS, David SATIJN, Rik RADEMAKER, Paul PARREN, Friederike GIESEKE, Ugur SAHIN
  • Bispecific antibodies against CD3 and CD20
    Patent number: 10544220
    Abstract: Bispecific antibodies directed to CD3 and CD20 and uses of such bispecific antibodies, in particular use thereof in the treatment of diseases in which specific targeting and T cell-mediated killing of cells that express CD20 is desired.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 28, 2020
    Assignee: GENMAB A/S
    Inventors: Patrick Engelberts, Esther Breij, Rik Rademaker, Isil Altintas, David Satijn, Sandra Verploegen, Riemke Van Dijkhuizen Radersma, Edward Van Den Brink, Janine Schuurman, Paul Parren
  • Methods of inducing T cell activation by administering an antibody comprising CD40 and 4-1BB (CD137) binding domains
    Patent number: 10457735
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: October 29, 2019
    Assignees: BIONTECH SE, GENMAB A/S
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren
  • HUMANIZED OR CHIMERIC CD3 ANTIBODIES
    Publication number: 20190284278
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Application
    Filed: July 14, 2016
    Publication date: September 19, 2019
    Inventors: Rik RADEMAKER, Isil ALTINTAS, Patrick ENGELBERTS, Janine SCHUURMAN, Paul PARREN
  • Humanized or chimeric CD3 antibodies
    Patent number: 10407501
    Abstract: The present invention relates to humanized or chimeric antibodies binding CD3. It furthermore relates to bispecific antibodies, compositions, pharmaceutical compositions, use of said antibodies in the treatment of a disease, and method of treatment.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: September 10, 2019
    Assignee: GENMAB A/S
    Inventors: Edward Norbert Van Den Brink, Joost J. Neijssen, Aran Frank Labrijn, Joyce Meesters, Janine Schuurman, Isil Altintas, Paul Parren, Rik Rademaker
  • AGONISTIC TNF RECEPTOR BINDING AGENTS
    Publication number: 20180194849
    Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.
    Type: Application
    Filed: January 8, 2016
    Publication date: July 12, 2018
    Inventors: Ugur Sahin, Friederike Gieseke, Isil Altintas, David Satijn, Paul Parren